Healthcare & Pharmaceutical

Our global reach gives clients access to Grayling professionals with an in-depth knowledge of national and regional variations of healthcare regulation and policy; particularly as regards reimbursement for Rx medicines.  Grayling pulls together creative and targeted programmes for clients that include public-focused disease awareness campaigns, lobbying and direct advocacy to government.

Health and Pharmaceutical communication throws up a number of challenges in each market.  For example, in many European countries it is illegal to publicise drug brands and sometimes drug active ingredients.  Elsewhere, in some developing countries there is very limited public reimbursement and the private market is dominant.  And in the USA, the new Administration’s proposed reforms may radically alter the healthcare sector.  Grayling has the knowledge and experience to help clients navigate these challenges to their advantage.

The landscape has changed for pharmaceutical companies, who are now faced with  lobbying cash-strapped governments to earmark healthcare budgets for new drugs; while against this environment, having to justify to their shareholders the shape and direction of R&D budgets.  What used to be a conversation between manufacturer and medical practitioner is now a public debate, where risk and cost adjusted drug efficacy is the main talking point. 

At Grayling we also have a very strong consumer lifestyle division working on campaigns for nutrition and healthy lifestyle products, sexual wellness awareness, hospital trusts, and campaigns to raise public disease awareness such as diabetes, dementia and breast cancer.  We use our sector expertise to inform consumer media of complex health issues in a way which is compelling, responsible and accurate.